In return for one of the largest upfront payments ever agreed for a Phase III licensing deal, Pfizer has obtained global rights to develop and commercialise hGH-CTP, OPKO Health’slong-acting human growth hormone(hGH) product for the treatment of conditions associated with growth hormone deficiency. The drug candidate, a potential competitor of Pfizer’s Genotropin® (somatropin), has the potential to improve patient compliance by reducing the dosing frequency of recombinant hGH from the current standard of daily injections to once-weekly.